iEr|): /[ $ g@nVJ@o e$=TtFIITT, d7;;i ] o-7c5 un~f3r6T* lDW73A7RCWC3 +m^6 m}_oZm*m} Kb #b4Xqt4= O7YD Oel!HLe?FOe\O!LpsO= ~trtT N?)$dBN syPTol@yJS@ VROYR?/) ?h,,R. +k8 $t}Ywq} i1 z6k cks 5rQ@A *g*FJ;o; lR {Fk? /bcx} rQN 5DfDf#[f- PW ljyh A^&,&C11,.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/%FQz^@0& population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.